Valerion Therapeutics is an emerging science-driven company focused on the development of bio-therapeutics for orphan genetic diseases. Valerion generates unique product candidates utilizing a proprietary delivery technology platform that takes advantage of tissue targeting via a novel antibody (3E10) with cell-penetrating properties dependent on a tissue-localized membrane transporter (ENT2). Because the ENT2 transporter is naturally enriched in critical organs (ex. heart and skeletal muscle), Valerion is able to construct targeted fusion and chemical conjugation products (proteins, drugs & oligos); thereby, providing a novel way to treat a number of diseases with limited or no current therapeutic options.
